论文部分内容阅读
为了探讨原发性肝癌患者脾脏免疫状态，分别检测原发性肝癌与腹腔良性疾病（对照）脾静脉血及外周静脉血细胞免疫和体液免疫指标，结果显示：①与正常人的外周血正常值比较，两组病人Ｔ细胞亚群ＣＤ系列含量差异无显著性（Ｐ＞０．０５）；②原发性肝癌与腹腔良性疾病进行比较，结果无论是脾静脉血还是外周静脉血，ＣＤ３、ＣＤ４、ＣＤ４／ＣＤ８含量均比腹腔良性疾病增高（Ｐ＜０．０５），而ＣＤ８含量差异无显著性（Ｐ＞０．０５）；③两组病人体液免疫指标差异无显著性（Ｐ＞０．０５）；提示原发性肝癌患者脾脏抗肿瘤正性免疫功能处于活跃状态，细胞免疫不但未受到抑制，反而增强，甚至高于正常人，而体液免疫则不受影响。
To investigate the immune status of spleen in patients with primary liver cancer, immunohistochemical and humoral immunity indices of spleen venous blood and peripheral venous blood were measured in primary liver cancer and benign intra-abdominal disease (control). The results showed that: 1 Compared with the normal values of normal blood There was no significant difference in the CD series content of T cell subsets between the two groups (P>0.05); 2 The comparison of primary liver cancer and benign intraperitoneal disease resulted in splenic venous blood or peripheral venous blood, CD3, CD4, CD4/CD8 content was higher than that of benign intra-abdominal disease (P<0.05), but there was no significant difference in CD8 content (P>0.05).3 There was no significant difference in humoral immune index between the two groups (P>0.05). The positive anti-tumor immune function of the spleen of patients with primary liver cancer is active. The cellular immunity is not only inhibited, but is even stronger than normal, and humoral immunity is not affected.